Cover
Cover | 6 Months Ended |
Jun. 30, 2022 | |
Cover [Abstract] | |
Document Type | S-1 |
Amendment Flag | false |
Entity Registrant Name | Therapeutic Solutions International, Inc. |
Entity Central Index Key | 0001419051 |
Entity Primary SIC Number | 2833 |
Entity Tax Identification Number | 45-1226465 |
Entity Incorporation, State or Country Code | NV |
Entity Address, Address Line One | 701 Wild Rose Lane |
Entity Address, City or Town | Elk City |
Entity Address, State or Province | ID |
Entity Address, Postal Zip Code | 83525 |
City Area Code | 760 |
Local Phone Number | 295-7208 |
Entity Filer Category | Non-accelerated Filer |
Entity Small Business | true |
Entity Emerging Growth Company | false |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Current assets: | |||
Cash and cash equivalents | $ 197,286 | $ 94,036 | $ 252,147 |
Restricted cash | 11,003 | 10,223 | 10,202 |
Accounts receivable | 31,837 | 16,613 | 2,441 |
Inventory | 62,566 | 39,817 | 5,399 |
Prepaid expenses and other current assets | 530,510 | 959,307 | 77,328 |
Total current assets | 833,202 | 1,119,996 | 347,517 |
Property and equipment, net | 281,698 | 284,024 | 5,059 |
Right-of-use asset | 21,530 | 34,184 | 58,976 |
Other assets | 3,405,003 | 277,571 | 191,922 |
Total assets | 4,541,433 | 1,715,775 | 603,474 |
Current liabilities: | |||
Accounts payable | 361,597 | 394,035 | 302,477 |
Accounts payable-related parties | 7,225 | 9,791 | 7,210 |
Accrued expenses and other current liabilities | 515,024 | 487,208 | 593,925 |
Lease liability | 19,377 | 25,374 | 24,792 |
Notes payable, current portion | 4,638 | 4,071 | |
Convertible notes payable, net of discount of $225,800 and $195,162, at December 31, 2021 and 2020, respectively | 88,117 | 79,200 | 37,338 |
Notes payable-related parties, net | 975,739 | 965,211 | 944,098 |
Derivative liabilities | 342,344 | 531,525 | 437,549 |
Total current liabilities | 2,314,061 | 2,496,415 | 2,347,389 |
LONG TERM LIABILITIES | |||
Notes payable, net of current portion | 12,779 | 15,532 | |
Lease liability, net of current portion | 2,153 | 8,810 | 34,184 |
TOTAL LIABILITIES | 2,328,993 | 2,520,757 | 2,381,573 |
Commitments and contingencies | |||
Shareholders’ Deficit: | |||
Preferred stock, $ 0.001 par value; 5,000,000 shares authorized | |||
Common stock, $ 0.001 par value; 3,500,000,000 shares authorized; 2,311,123,860 and 2,233,741,391 shares issued and outstanding at December 31, 2021 and 2020, respectively. | 2,552,228 | 2,311,125 | 2,233,742 |
Additional paid-in capital | 15,467,138 | 10,899,139 | 7,041,960 |
Subscription receivable | (21,000) | (21,000) | (21,000) |
Accumulated deficit | (15,785,926) | (13,994,246) | (11,032,801) |
Total shareholders’ deficit | 2,212,440 | (804,982) | (1,778,099) |
Total liabilities and shareholders’ deficit | $ 4,541,433 | $ 1,715,775 | $ 603,474 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | |||
Debt instrument, unamortized discount, current | $ 249,383 | $ 225,800 | $ 195,162 |
Preferred stock, par or stated value per share | $ 0.001 | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 | 5,000,000 |
Common stock, par or stated value per share | $ 0.001 | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 3,500,000,000 | 3,500,000,000 | 3,500,000,000 |
Common stock, shares, issued | 2,552,228,460 | 2,311,123,860 | 2,233,741,391 |
Common stock, shares, outstanding | 2,552,228,460 | 2,311,123,860 | 2,233,741,391 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | ||||||
Net sales | $ 38,749 | $ 23,444 | $ 123,647 | $ 44,505 | $ 145,956 | $ 62,681 |
Cost of goods sold | 8,709 | 4,086 | 24,647 | 15,167 | 42,544 | 12,792 |
Gross profit | 30,040 | 19,358 | 99,000 | 29,338 | 103,412 | 49,889 |
Operating expenses: | ||||||
General and administrative | 143,716 | 28,640 | 183,723 | 65,451 | 138,710 | 88,429 |
Salaries, wages, and related costs | 112,533 | 130,767 | 226,818 | 235,230 | 436,555 | 849,717 |
Consulting fees | 142,010 | 76,147 | 229,126 | 117,330 | 264,540 | 119,209 |
Legal and professional fees | 109,271 | 75,146 | 159,363 | 143,898 | 773,203 | 280,124 |
Research and development | 597,893 | 132,085 | 902,052 | 151,782 | 794,750 | 561,990 |
Total operating expenses | 1,105,423 | 442,785 | 1,701,082 | 713,691 | 2,407,758 | 1,899,469 |
Loss from operations | (1,075,383) | (423,427) | (1,602,082) | (684,353) | (2,304,346) | (1,849,580) |
Other income (expense): | ||||||
Loss on derivative liabilities | (43,184) | (84,298) | (109,716) | (432,553) | (539,006) | (247,620) |
Change in fair value of derivative liabilities | 123,202 | 66,566 | 265,508 | 570,752 | 494,501 | 206,501 |
Interest expense | (195,392) | (196,083) | (345,390) | (278,011) | (611,794) | (302,481) |
Other expense | (6,721) | |||||
Total other income (expense) | (115,374) | (213,815) | (189,598) | (139,812) | (656,299) | (350,321) |
LOSS BEFORE PROVISION FOR INCOME TAXES | (2,960,645) | (2,199,901) | ||||
Provision for income taxes | 800 | |||||
Net loss | $ (1,190,757) | $ (637,242) | $ (1,791,680) | $ (824,165) | $ (2,961,445) | $ (2,199,901) |
Net loss per share - basic and diluted | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 |
Weighted average shares outstanding - basic and diluted | 2,541,429,204 | 2,250,426,426 | 2,468,126,294 | 2,245,257,452 | 2,263,126,970 | 1,911,855,232 |
Consolidated Statement of Chang
Consolidated Statement of Changes in Shareholders' Deficit - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Subscription Receivable [Member] | Retained Earnings [Member] | Total |
Balance at Dec. 31, 2019 | $ 1,614,628 | $ 5,183,228 | $ (8,832,900) | $ (2,035,044) | |
Balance, shares at Dec. 31, 2019 | 1,614,627,811 | ||||
Common stock issued for services | $ 173,500 | 496,250 | 669,750 | ||
Common stock issued for services, shares | 173,500,000 | ||||
Common stock issued for salaries | $ 78,682 | 417,218 | 495,900 | ||
Common stock issued for salaries, shares | 78,681,818 | ||||
Common stock sold | $ 192,376 | 436,124 | (21,000) | 607,500 | |
Common stock sold, shares | 192,375,737 | ||||
Offering costs | (19,456) | (19,456) | |||
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities | $ 174,556 | 88,326 | 262,882 | ||
Common stock issued for conversion of convertible notes, accrued interest, and derivative liabilities, shares | 174,556,025 | ||||
Relief of derivative liabilities | 440,270 | 440,270 | |||
Net loss | (2,199,901) | (2,199,901) | |||
Balance at Dec. 31, 2020 | $ 2,233,742 | 7,041,960 | (21,000) | (11,032,801) | (1,778,099) |
Balance, shares at Dec. 31, 2020 | 2,233,741,391 | ||||
Common stock issued for services | $ 3,500 | 167,900 | 171,400 | ||
Common stock issued for services, shares | 3,500,000 | ||||
Common stock issued for prepaid fees | $ 3,000 | 196,500 | 199,500 | ||
Common stock issued for prepaid fees, shares | 3,000,000 | ||||
Common stock issued for accrued salaries | $ 7,545 | 191,455 | 199,000 | ||
Common stock issued for accrued salaries, shares | 7,544,848 | ||||
Common stock issued for cash | $ 3,571 | 221,927 | 225,498 | ||
Common stock issued for cash, shares | 3,571,679 | ||||
Common stock issued for prepaid expenses | $ 500 | 22,700 | 23,200 | ||
Common stock issued for prepaid expenses, shares | 500,000 | ||||
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities | $ 7,664 | 238,786 | 246,450 | ||
Common stock issued for conversion of convertible notes, accrued interest, and derivative liabilities, shares | 7,663,763 | ||||
Relief of derivative liabilities | 240,687 | 240,687 | |||
Net loss | (824,165) | (824,165) | |||
Balance at Jun. 30, 2021 | $ 2,259,522 | 8,321,915 | (21,000) | (11,856,966) | (1,296,529) |
Balance, shares at Jun. 30, 2021 | 2,259,521,681 | ||||
Balance at Dec. 31, 2020 | $ 2,233,742 | 7,041,960 | (21,000) | (11,032,801) | (1,778,099) |
Balance, shares at Dec. 31, 2020 | 2,233,741,391 | ||||
Common stock issued for services | $ 21,000 | 837,900 | 858,900 | ||
Common stock issued for services, shares | 21,000,000 | ||||
Common stock issued for salaries | $ 8,342 | 231,457 | 239,799 | ||
Common stock issued for salaries, shares | 8,341,723 | ||||
Common stock issued for land development | $ 1,500 | 57,400 | 58,900 | ||
Common stock issued for land development, shares | 1,500,000 | ||||
Common stock issued for prepaid fees | $ 20,000 | 1,452,450 | 1,472,450 | ||
Common stock issued for prepaid fees, shares | 20,000,000 | ||||
Common stock issued for cash | $ 4,850 | 280,649 | 285,499 | ||
Common stock issued for cash, shares | 4,850,075 | ||||
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities | $ 21,691 | 508,044 | 529,735 | ||
Common stock issued for conversion of convertible notes, accrued interest, and derivative liabilities, shares | 21,690,671 | ||||
Relief of derivative liabilities | 489,279 | 489,279 | |||
Net loss | (2,961,445) | (2,961,445) | |||
Balance at Dec. 31, 2021 | $ 2,311,125 | 10,899,139 | (21,000) | (13,994,246) | (804,982) |
Balance, shares at Dec. 31, 2021 | 2,311,123,860 | ||||
Balance at Mar. 31, 2021 | $ 2,244,453 | 7,481,248 | (21,000) | (11,219,724) | (1,515,023) |
Balance, shares at Mar. 31, 2021 | 2,244,453,070 | ||||
Common stock issued for services | $ 3,500 | 167,900 | 171,400 | ||
Common stock issued for services, shares | 3,500,000 | ||||
Common stock issued for salaries | $ 2,745 | 136,255 | 139,000 | ||
Common stock issued for salaries, shares | 2,744,848 | ||||
Common stock issued for prepaid fees | $ 500 | 26,500 | 27,000 | ||
Common stock issued for prepaid fees, shares | 500,000 | ||||
Common stock issued for cash | $ 160 | 7,839 | 7,999 | ||
Common stock issued for cash, shares | 160,000 | ||||
Common stock issued for prepaid expenses | $ 500 | 22,700 | 23,200 | ||
Common stock issued for prepaid expenses, shares | 500,000 | ||||
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities | $ 7,664 | 238,786 | 246,450 | ||
Common stock issued for conversion of convertible notes, accrued interest, and derivative liabilities, shares | 7,663,763 | ||||
Relief of derivative liabilities | 240,687 | 240,687 | |||
Net loss | (637,242) | (637,242) | |||
Balance at Jun. 30, 2021 | $ 2,259,522 | 8,321,915 | (21,000) | (11,856,966) | (1,296,529) |
Balance, shares at Jun. 30, 2021 | 2,259,521,681 | ||||
Balance at Dec. 31, 2021 | $ 2,311,125 | 10,899,139 | (21,000) | (13,994,246) | (804,982) |
Balance, shares at Dec. 31, 2021 | 2,311,123,860 | ||||
Common stock issued for services | $ 16,000 | 391,200 | 407,200 | ||
Common stock issued for services, shares | 16,000,000 | ||||
Common stock issued for salaries | $ 1,034 | 28,965 | 29,999 | ||
Common stock issued for salaries, shares | 1,034,482 | ||||
Common stock issued for prepaid fees | $ 6,000 | 142,820 | 148,820 | ||
Common stock issued for prepaid fees, shares | 6,000,000 | ||||
Common stock issued for cash | $ 44,500 | 400,500 | 445,000 | ||
Common stock issued for cash, shares | 44,500,000 | ||||
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities | $ 24,167 | 297,957 | 322,124 | ||
Common stock issued for conversion of convertible notes, accrued interest, and derivative liabilities, shares | 24,167,728 | ||||
Relief of derivative liabilities | 348,389 | 348,389 | |||
Net loss | (1,791,680) | (1,791,680) | |||
Common stock issued for license | $ 149,402 | 2,958,168 | 3,107,570 | ||
Common stock issued for license, shares | 149,402,390 | ||||
Balance at Jun. 30, 2022 | $ 2,552,228 | 15,467,138 | (21,000) | (15,785,926) | 2,212,440 |
Balance, shares at Jun. 30, 2022 | 2,552,228,460 | ||||
Balance at Mar. 31, 2022 | $ 2,514,998 | 14,506,200 | (121,000) | (14,595,169) | 2,305,029 |
Balance, shares at Mar. 31, 2022 | 2,514,998,180 | ||||
Common stock issued for services | $ 16,000 | 391,200 | 407,200 | ||
Common stock issued for services, shares | 16,000,000 | ||||
Common stock issued for prepaid fees | $ 6,000 | 142,820 | 148,820 | ||
Common stock issued for prepaid fees, shares | 6,000,000 | ||||
Common stock issued for cash | 100,000 | 100,000 | |||
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities | $ 15,230 | 191,619 | 206,849 | ||
Common stock issued for conversion of convertible notes, accrued interest, and derivative liabilities, shares | 15,230,280 | ||||
Relief of derivative liabilities | 235,299 | 235,299 | |||
Net loss | (1,190,757) | (1,190,757) | |||
Balance at Jun. 30, 2022 | $ 2,552,228 | $ 15,467,138 | $ (21,000) | $ (15,785,926) | $ 2,212,440 |
Balance, shares at Jun. 30, 2022 | 2,552,228,460 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | 60 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | |
Cash flows from operating activities | |||||||
Net loss | $ (1,190,757) | $ (637,242) | $ (1,791,680) | $ (824,165) | $ (2,961,445) | $ (2,199,901) | $ 14,200,000 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
Stock-based compensation to consultants | 256,600 | 29,500 | 397,750 | 100,600 | |||
Stock-based compensation to related parties | 150,600 | 141,900 | 461,150 | 1,065,050 | |||
Loss on derivative liabilities | 43,184 | 84,298 | 109,716 | 432,553 | 539,006 | 247,620 | |
Change in fair value of derivative liabilities | (123,202) | (66,566) | (265,508) | (570,752) | (494,501) | (206,501) | |
Gain on extinguishment of debt | (16,479) | ||||||
Amortization of prepaid stock-based compensation | 624,165 | 40,438 | 480,135 | ||||
Amortization of debt discount | 313,917 | 248,238 | 541,612 | 251,801 | |||
Patent amortization | 104,805 | 3,296 | 11,295 | 6,591 | |||
Depreciation | 2,326 | 1,331 | 6,772 | 389 | |||
Changes in operating assets and liabilities: | |||||||
Accounts receivable | (15,224) | (7,973) | (14,172) | 463 | |||
Inventory | (22,749) | (61,334) | (34,418) | (219) | |||
Prepaid expenses and other current assets | 28,785 | 47,322 | 64,777 | (15,140) | |||
Right-of-use asset | 12,654 | 12,270 | 24,792 | (53,357) | |||
Accounts payable | (32,440) | 701 | 91,557 | (22,458) | |||
Accounts payable - related parties | (2,566) | 2,513 | 2,581 | (5,505) | |||
Accrued expenses and other current liabilities | 87,899 | 75,556 | 188,979 | 130,611 | |||
Lease liability | (12,654) | (12,270) | (24,792) | 53,356 | |||
Net cash used in operating activities | (451,354) | (440,876) | (718,922) | (663,079) | |||
CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||
Purchases of property and equipment | (237,365) | (260,565) | (5,448) | ||||
Purchase of license | (200,000) | ||||||
Deposits | 4,015 | 4,015 | |||||
Net cash used in investing activities | (200,000) | (233,350) | (256,550) | (5,448) | |||
Cash flows from financing activities | |||||||
Payments on notes payable to related party | (2,430) | (2,094) | (4,799) | (25,244) | |||
Proceeds from convertible notes payable | 315,000 | 252,500 | 538,750 | 315,000 | |||
Proceeds from notes payable | 16,479 | ||||||
Payments on notes payable | (2,186) | (2,068) | |||||
Proceeds from sale of common stock | 445,000 | 225,498 | 285,499 | 588,044 | |||
Net cash provided by financing activities | 755,384 | 475,904 | 817,382 | 894,279 | |||
Net increase (decrease) in cash, cash equivalents and restricted cash | 104,030 | (198,322) | (158,090) | 225,752 | |||
Cash, cash equivalents and restricted cash at beginning of year | 104,259 | 262,349 | 262,349 | 36,597 | |||
Cash, cash equivalents and restricted cash at end of year | 208,289 | 64,027 | 208,289 | 64,027 | 104,259 | 262,349 | 104,259 |
Supplemental cash flow information: | |||||||
Cash paid for interest | 229,126 | 1,133 | 3,312 | 6,369 | |||
Cash paid for income taxes | 1,570 | 800 | 800 | 1,585 | |||
Non-cash investing and financing transactions: | |||||||
Original issuance discount on convertible notes payable | 22,500 | 14,750 | 33,500 | 21,500 | |||
Debt discount recorded in connection with derivative liability | 315,000 | 252,500 | 538,750 | 315,000 | |||
Common stock issued in conversion of convertible notes payable and interest | 670,513 | 487,137 | 1,019,014 | 713,152 | |||
Property and equipment purchased with note payable | 21,671 | ||||||
Common stock issued for prepaid fees | 148,820 | 199,500 | 1,472,450 | ||||
Common stock issued for accrued salaries | 29,999 | 199,000 | 239,799 | ||||
Accrued interest added to principal | 12,958 | 12,956 | 25,912 | 26,876 | |||
Common stock issued for license | 3,107,570 | ||||||
Common stock issued for land development | 23,200 | 58,900 | |||||
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: | |||||||
Cash and cash equivalents | 197,286 | 53,804 | 197,286 | 53,804 | 94,036 | 252,147 | 94,036 |
Restricted cash | 11,003 | 10,223 | 11,003 | 10,223 | 10,223 | 10,202 | 10,223 |
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows: | $ 208,289 | $ 64,027 | $ 208,289 | $ 64,027 | $ 104,259 | $ 262,349 | $ 104,259 |
Organization and Business Descr
Organization and Business Description | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Organization and Business Description | Note 1 – Organization and Business Description Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 Business Description Currently, the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, lung pathologies, and for daily health. Cellular Division The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability. Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021 the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE. On August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%. In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.” The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells. Most recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system to kill blood vessels feeding cancer but sparing healthy blood vessels. These discoveries are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production. On May 9, 2022, the Company filed an Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells under IND Serial # 28508. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 Management does not expect existing cash as of June 30, 2022, to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of June 30, 2022, the Company has incurred losses totaling $ 1.8 | Note 1 – Nature of business Organization and Business Description Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 Currently, the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSI is developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. Cellular Division The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability. Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021 the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE. On August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91% In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.” The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells. Most recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system to kill blood vessels feeding cancer, but sparing healthy blood vessels. These discoveries are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production. Management does not expect existing cash as of December 31, 2021 or as of March 31, 2022 to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2021, the Company has incurred losses totaling $ 14.2 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 |
Basis of presentation and signi
Basis of presentation and significant accounting policies | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Accounting Policies [Abstract] | ||
Basis of presentation and significant accounting policies | Note 2 – Basis of presentation and significant accounting policies Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Returns. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Shipping. Out of Stock. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 0 Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items. Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 8 containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 342,344 531,525 Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of June 30, 2022 and December 31, 2021, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the six months ended June 30, 2022: Schedule of Change in Derivative Liability Balance, December 31, 2021 $ 531,525 Issuance of new derivative liabilities 424,716 Conversions to paid-in capital (348,389 ) Change in fair market value of derivative liabilities (265,508 ) Balance, June 30, 2022 $ 342,344 Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of June 30, 2022 and 2021, a total of 167,223,808 286,251,995 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the six months ended June 30, 2022 and 2021 was $ 2,326 1,331 Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the six months ended June 30, 2022 and 2021 was $ 104,805 3,296 Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 902,052 151,782 Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares. Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 21,530 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of adoption of this ASU and determined that it will have no significant impact on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures. | Note 2 – Basis of presentation and significant accounting policies Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries. Revenue Recognition The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retai Inspection of Goods & Rejection. Risk of Loss. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued) Retail policies of e-commerce: Returns. Shipping. Out of Stock. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 12,349 Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items. Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2021 and 2020, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 531,525 437,549 Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued) Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2021 and 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the years ended December 31, 2021 and 2020: Schedule of Change in Derivative Liability Balance, December 31, 2019 $ 521,700 Issuance of new derivative liabilities 562,620 Conversions to paid-in capital (440,270 ) Change in fair market value of derivative liabilities (206,501 ) Balance, December 31, 2020 437,549 Issuance of new derivative liabilities 1,077,756 Conversions to paid-in capital (489,279 ) Change in fair market value of derivative liabilities (494,501 ) Balance, December 31, 2021 $ 531,525 Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2021 and 2020, a total of 95,273,690 579,347,525 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued) Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the years ended December 31, 2021 and 2020 was $ 6,772 389 Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2021 and 2020 was $ 11,295 6,591 Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 794,750 561,990 Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares. Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 34,184 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued) Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of adoption of this ASU and determined that it will have no significant impact on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures. |
Restricted cash
Restricted cash | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Cash and Cash Equivalents [Abstract] | ||
Restricted cash | Note 3 – Restricted cash Included in current assets is a $ 10,000 0.6 This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011 | Note 3 – Restricted cash Included in current assets is a $ 10,000 0.6 This certificate matures on June 17, 2022, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011 |
Prepaid expense and other curre
Prepaid expense and other current assets | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Prepaid Expense And Other Current Assets | ||
Prepaid expense and other current assets | Note 4 – Prepaid expense and other current assets Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets June 30, 2022 December 31, 2021 Prepaid consulting $ 461,820 $ 930,893 Insurance 1,094 987 Prepaid costs 67,596 27,427 Total $ 530,510 $ 959,307 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 | Note 4 – Prepaid expense and other current assets Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets December 31, 2021 December 31, 2020 Prepaid consulting $ 930,893 $ 76,663 Insurance 987 665 Prepaid costs 27,427 - Total $ 959,307 $ 77,328 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 |
Fixed assets
Fixed assets | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Property, Plant and Equipment [Abstract] | ||
Fixed assets | Note 5 – Fixed assets Fixed assets consist of the following: Schedule of Fixed Assets June 30, 2022 December 31, 2021 Land $ 235,223 $ 235,223 Vehicles 50,514 50,514 Computer hardware 5,935 5,935 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 301,159 301,159 Accumulated depreciation (19,461 ) (17,135 ) Property and equipment, net $ 281,698 $ 284,024 Depreciation expense was $ 2,326 1,331 | Note 5 – Fixed assets Fixed assets consist of the following: Schedule of Fixed Assets December 31, 2021 December 31, 2020 Land $ 235,223 $ - Vehicles 50,514 - Computer hardware 5,935 10,747 Office furniture and equipment 7,912 3,639 Shipping and other equipment 1,575 7,023 Total 301,159 21,409 Accumulated depreciation (17,135 ) (16,350 ) Property and equipment, net $ 284,024 $ 5,059 Depreciation expense was $ 6,772 389 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 |
Other assets
Other assets | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | ||
Other assets | Note 6 – Other assets Other assets consist of the following: Schedule of Other Assets June 30, 2022 December 31, 2021 Prepaid consulting $ 33,340 $ 108,673 Deposit 39,823 39,823 Licenses, net 3,331,840 129,075 Total $ 3,405,003 $ 277,571 As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2. On February 9, 2021, the Company issued a Convertible Promissory Note (CPN) to JadiCell LLC that was never fully executed while the parties worked to finalize the agreement that resulted in an Exclusive Patent License Agreement (EPLA) being executed on 9/15/2021. Finally, a Settlement Agreement was entered into on February 23, 2022. On February 23, 2022, we issued 149,402,390 0.0208 3,107,570 December 31, 2032 10 five years 200,000 1.8 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses June 30, 2022 December 31, 2021 Licenses $ 3,461,122 $ 153,552 Accumulated amortization (129,282 ) (24,477 ) Licenses, net $ 3,331,840 $ 129,075 Amortization expense for the six months ended June 30, 2022 and 2021 was $ 104,805 3,296 | Note 6 – Other assets Other assets consist of the following: Schedule of Other Assets December 31, 2021 December 31, 2020 Prepaid consulting $ 108,673 $ 39,914 Deposit 39,823 11,638 Licenses, net 129,075 140,370 Total $ 277,571 $ 191,922 Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses December 31, 2021 December 31, 2020 License $ 153,552 $ 153,552 Accumulated amortization (24,477 ) (13,182 ) Licenses, net $ 129,075 $ 140,370 As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2. Forward looking the Company intends to file an Investigational New Drug Application (IND) for brain injured patients who have been intensively cared for and mechanically ventilated due to covid-19 illness and a second IND for CTE/TBI as well in keeping with the spirit of the licensing agreement to advance the Jadi Cell through to FDA Approval for CTE/TBI. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 |
Notes Payable-Related Party
Notes Payable-Related Party | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Debt Disclosure [Abstract] | ||
Notes Payable-Related Party | Note 7 - Notes Payable-Related Party At June 30, 2022 and December 31, 2021, the Company has unsecured interest-bearing demand notes outstanding to certain officers and directors amounting to $ 975,739 965,211 12,956 12,956 251,000 0.004 0.005 | Note 8 – Notes payable-related parties Notes Payable-Related Party Notes payable-related parties consist of: Schedule of Notes Payable Related Parties December 31, 2021 December 31, 2020 $ 2,356 $ 7,054 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10 December 31, 2019 $ 2,356 $ 7,054 Three notes payable – Chief Executive Officer, unsecured, including interest at 8 10 10 December 31, 2019 27,577 26,064 One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues 534,544 534,646 Note payable – Chief Financial Officer, unsecured, including interest at 8 December 31, 2019 118,400 112,000 Three notes payable – Business Advisory Board Member, unsecured, including interest at 8 10 0.005 0.004 April 20, 2019 282,334 264,334 965,211 944,098 Less debt discount - - $ 965,211 $ 944,098 |
Convertible Notes Payable
Convertible Notes Payable | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Debt Disclosure [Abstract] | ||
Convertible Notes Payable | Note 8 – Convertible Notes Payable At various times during the six months ended June 30, 2022, the Company entered into convertible promissory notes with principal amounts totaling $ 337,500 315,000 22,500 10 12 January 1, 2023 to June 27, 2023 The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. 167,223,808 Derivative liabilities These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period. For the notes issued during the six months ended June 30, 2022, the Company valued the conversion feature on the date of issuance resulting in an initial liability of $ 424,716 109,716 0.0127 0.0143 0.020 0.027 0 158 216 0.48 2.89 one year THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 During the six months ended June 30, 2022, convertible notes with principal and accrued interest balances totaling $ 322,124 24,167,728 348,389 0.012 0.016 0.018 0.026 0 166 191 0.51 2.88 0.49 On June 30, 2022, the derivative liabilities on the remaining convertible notes were revalued at $ 342,344 265,508 0.0129 0.021 0 127 165 2.80 0.54 0.99 The Company amortizes the discounts over the term of the convertible promissory notes using the straight-line method which is similar to the effective interest method. During the six months ended June 30, 2022 and 2021, the Company amortized $ 313,917 248,238 249,383 amortized through June 2023 | Note 7 – Convertible notes payable Convertible Notes Payable At various times during the year ended December 31, 2021, the Company entered into convertible promissory notes with principal amounts totaling $ 572,250 538,750 33,500 10 12 mature on dates ranging from January 25, 2022 to December 15, 2022 The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150% 95,273,690 On various dates throughout the year ended December 31, 2020, the Company entered into seven convertible promissory notes with principal amounts totaling $ 336,500 315,000 21,500 12 mature on dates ranging from February 3, 2021 to December 17, 2021 The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to 61% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150% 579,347,525 Derivative liabilities These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 7 – Convertible notes payable (Continued) For the seven notes issued during the year ended December 31, 2020, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $ 562,620 247,620 0.0008 0.0042 0.0023 0.0056 0 237 260 0.17 1.48 one year During the year ended December 31, 2020, convertible notes principal plus their accrued interest totaling $ 262,882 174,556,025 440,270 0.00055 0.0039 0.001 0.010 0 170 305 0.12 0.89 0.07 0.50 On December 31, 2020, the derivative liabilities on the remaining four convertible notes were revalued at $ 437,539 206,501 0.0029 0.0064 0 241 254 0.12 0.76 0.96 For the notes issued during the year ended December 31, 2021, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $ 1,077,756 539,006 0.0039 0.0351 0.0217 0.0540 0 197 264 0.05 0.29 one year During the year ended December 31, 2021, convertible notes principal plus their accrued interest totaling $ 529,735 21,690,671 489,279 0.0136 0.035 0.022 0.057 0 125 251 0.06 0.29 0.48 0.50 On December 31, 2021, the derivative liabilities on the remaining five convertible notes were revalued at $ 531,525 494,501 0.0123 0.0127 0.029 0 165 218 0.39 0.53 0.96 The Company amortizes the discounts over the term of the convertible promissory notes using the straight line method which is similar to the effective interest method. During the years ended December 31, 2021 and 2020, the Company amortized $ 541,612 251,801 225,800 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 |
Equity
Equity | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Equity [Abstract] | ||
Equity | Note 9 – Equity Our authorized capital stock consists of an aggregate of 3,505,000,000 3,500,000,000 0.001 5,000,000 2,552,228,460 In 2021, we issued 4,850,075 285,500 In 2021, we issued 21,000,000 858,900 In 2021, we issued 8,341,723 239,799 In 2021, we issued 1,500,000 58,900 In 2021, we issued 21,690,671 1,019,014 In 2022, we issued 44,500,000 445,000 In 2022, we issued 16,000,000 407,200 In 2022, we issued 1,034,482 29,999 In 2022, we issued 149,402,390 3,107,570 In 2022, we issued 24,167,728 322,124 In 2022, we issued 6,000,000 148,820 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 | Note 11 – Equity Our authorized capital stock consists of an aggregate of 3,505,000,000 3,500,000,000 0.001 5,000,000 2,311,123,860 no In 2020, we issued 192,375,737 607,500 In 2020, we issued 173,500,000 669,750 In 2020, we issued 78,681,818 495,900 In 2020, we issued 174,556,025 703,152 In 2021, we issued 4,850,075 285,500 In 2021, we issued 21,000,000 858,900 In 2021, we issued 8,341,723 239,799 In 2021, we issued 1,500,000 58,900 In 2021, we issued 21,690,671 1,019,014 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 |
Subsequent events
Subsequent events | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Subsequent Events [Abstract] | ||
Subsequent events | Note 10 – Subsequent events On July 13, 2022, we issued 2,777,778 35,000 On July 15, 2022, we issued 1,701,389 21,438 On July 25, 2022, we issued 4,095,000 51,188 On August 4, 2022, we issued 5,000,000 .02 On August 4, 2022, the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination, on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall vote together with the holders of Common Stock as a single class. On August 9, 2022, we issued 2 0.001 In accordance with ASC 855, the Company has analyzed its operations subsequent to August 18, 2022 through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements. | Note 14 – Subsequent events On January 4, 2022, we issued 1,034,482 30,000 On January 14, 2022,we issued 4,158,759 56,975 On February, 2022, we issued 4,778,689 58,300 On February 14, 2022, we issued 24,500,000 0.01 On February 24, 2022, we issued 10,000,000 0.01 On February 24, 2022, we issued 149,402,390 15,000,000 In accordance with ASC 855, the Company has analyzed its operations subsequent to December 31, 2021 through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements. |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | ||
Commitments and Contingencies | Note 11 – Commitments and Contingencies Effective March 1, 2020, the Company entered into a fifth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 36 April 30, 2023 Total rent expense for the six months is $ 12,522 The lease will expire in 2023. The weighted average discount rate used for this lease is 5 Future minimum lease payments as of December 31, 2022, are as follows: Schedule of Future Minimum Lease Payments For the year ending December 31, 2022 $ 13,062 2023 $ 8,612 As of March 25, 2022, we entered into an asset transfer and license agreement, which will be amortized over the life of the agreement. The agreement is for five years 200,000 1.8 | Note 13 – Commitments and Contingencies Effective March 1, 2020, the Company entered into a fifth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 36 April 30, 2023 During the year ended December 31, 2021 and 2020, the Company incurred rent expense of $ 22,768 25,993 The lease will expire in 2023. The weighted average discount rate used for this lease is 5 Schedule of Future Minimum Lease Payments 2022 26,460 2023 8,911 Total lease payment 35,371 Less: Imputed Interest (1,187 ) Present value of lease liabilities 34,184 Current portion (25,374 ) Non-current portion 8,810 Effective November 8, 2019, the Company entered into a royalty agreement with one of the officers, refer to Note 9. |
Related party transactions
Related party transactions | 12 Months Ended |
Dec. 31, 2021 | |
Related Party Transactions [Abstract] | |
Related party transactions | Note 9 – Related party transactions As of December 31, 2019 and 2018, the Company had accrued officers’ salary of $ 439,534 663,100 0.5 In 2020, the Company settled an accrual of wages with Timothy G. Dixon with a convertible note payable of $ 60,000 5 18,181,818 60,000 In 2020 we issued 122,000,000 437,400 In 2020 we issued 29,000,000 240,000 On June 15, 2020, we issued 20,000,000 106,000 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 9 – Related party transactions (continued) On July 17, 2020 we issued 22,500,000 154,500 In 2021, we issued 7,544,848 shares of common stock for $ 239,800 of accrued salaries to one officer of the Company under a Restricted Stock Award. On June 18, 2021, we issued 2,000,000 94,600 On November 30, 2021, we issued 7,000,000 224,000 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 |
Income taxes
Income taxes | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Income taxes | Note 10 – Income taxes The Company is subject to United States federal and state income taxes at an approximate rate of 30 Schedule of Income tax Expense December 31, 2021 December 31, 2020 Expected income tax at statutory rate $ (621,735 ) $ (458,619 ) State tax 168 168 Meals & Entertainments 295 - Permanent differences 404,577 295,578 Other (71,992 ) (336 ) Change in valuation allowance 289,487 163,209 Provision for income taxes $ 800 $ - The significant components of deferred income tax assets and liabilities at December 31, 2021 and 2020 are as follows: Schedule of Deferred Tax Assets and Liabilities December 31, 2021 December 31, 2020 Net operating loss carry-forward $ 1,450,896 $ 1,668,324 Valuation allowance (1,450,896 ) (1,668,324 ) Net deferred tax asset $ - $ - The Company has Federal net operating loss carryforwards of approximately $ 7.5 6.5 5.5 4.5 5 expires beginning in fiscal 2032 As of and for the years ended December 31, 2021 and 2020, management does not believe the Company has any uncertain tax positions. Accordingly, there are no recognized tax benefits at December 31, 2021 and 2020. The Company is subject to tax in the United States and files tax returns in the U.S. Federal jurisdiction and California state jurisdiction. The Company is subject to U.S. Federal, state and local income tax examinations by tax authorities starting in 2018. The Company currently is not under examination by any tax authority. |
Legal proceedings
Legal proceedings | 12 Months Ended |
Dec. 31, 2021 | |
Legal Proceedings | |
Legal proceedings | Note 12 – Legal proceedings From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods. However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations. |
Basis of presentation and sig_2
Basis of presentation and significant accounting policies (Policies) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Accounting Policies [Abstract] | ||
Basis of Presentation | Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. | Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. |
Principles of Consolidation | Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries. | Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries. |
Revenue Recognition | Revenue Recognition The Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Returns. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Shipping. Out of Stock. | Revenue Recognition The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retai Inspection of Goods & Rejection. Risk of Loss. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued) Retail policies of e-commerce: Returns. Shipping. Out of Stock. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 0 | Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 12,349 |
Inventories | Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items. | Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items. |
Derivative Liabilities | Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 8 containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 342,344 531,525 | Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2021 and 2020, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 531,525 437,549 |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of June 30, 2022 and December 31, 2021, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the six months ended June 30, 2022: Schedule of Change in Derivative Liability Balance, December 31, 2021 $ 531,525 Issuance of new derivative liabilities 424,716 Conversions to paid-in capital (348,389 ) Change in fair market value of derivative liabilities (265,508 ) Balance, June 30, 2022 $ 342,344 | Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued) Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2021 and 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the years ended December 31, 2021 and 2020: Schedule of Change in Derivative Liability Balance, December 31, 2019 $ 521,700 Issuance of new derivative liabilities 562,620 Conversions to paid-in capital (440,270 ) Change in fair market value of derivative liabilities (206,501 ) Balance, December 31, 2020 437,549 Issuance of new derivative liabilities 1,077,756 Conversions to paid-in capital (489,279 ) Change in fair market value of derivative liabilities (494,501 ) Balance, December 31, 2021 $ 531,525 |
Use of Estimates | Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. | Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. |
Comprehensive Loss | Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. | Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. |
Net Loss Per Share | Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of June 30, 2022 and 2021, a total of 167,223,808 286,251,995 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 | Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2021 and 2020, a total of 95,273,690 579,347,525 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued) |
Depreciation and Amortization | Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the six months ended June 30, 2022 and 2021 was $ 2,326 1,331 | |
Intangible Assets | Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the six months ended June 30, 2022 and 2021 was $ 104,805 3,296 | Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2021 and 2020 was $ 11,295 6,591 |
Long-lived Assets | Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. | Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. |
Research and Development | Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 902,052 151,782 | Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 794,750 561,990 |
Income Taxes | Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” | Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” |
Stock-Based Compensation | Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares. | Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares. |
Leases | Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 21,530 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 | Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 34,184 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2021 Note 2 – Basis of presentation and significant accounting policies (Continued) |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of adoption of this ASU and determined that it will have no significant impact on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures. | Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of adoption of this ASU and determined that it will have no significant impact on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures. |
Depreciation and Amortization | Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the years ended December 31, 2021 and 2020 was $ 6,772 389 |
Basis of presentation and sig_3
Basis of presentation and significant accounting policies (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Accounting Policies [Abstract] | ||
Schedule of Change in Derivative Liability | The following is the change in derivative liability for the six months ended June 30, 2022: Schedule of Change in Derivative Liability Balance, December 31, 2021 $ 531,525 Issuance of new derivative liabilities 424,716 Conversions to paid-in capital (348,389 ) Change in fair market value of derivative liabilities (265,508 ) Balance, June 30, 2022 $ 342,344 | The following is the change in derivative liability for the years ended December 31, 2021 and 2020: Schedule of Change in Derivative Liability Balance, December 31, 2019 $ 521,700 Issuance of new derivative liabilities 562,620 Conversions to paid-in capital (440,270 ) Change in fair market value of derivative liabilities (206,501 ) Balance, December 31, 2020 437,549 Issuance of new derivative liabilities 1,077,756 Conversions to paid-in capital (489,279 ) Change in fair market value of derivative liabilities (494,501 ) Balance, December 31, 2021 $ 531,525 |
Prepaid expense and other cur_2
Prepaid expense and other current assets (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Prepaid Expense And Other Current Assets | ||
Schedule of Prepaid Expenses and Other Current Assets | Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets June 30, 2022 December 31, 2021 Prepaid consulting $ 461,820 $ 930,893 Insurance 1,094 987 Prepaid costs 67,596 27,427 Total $ 530,510 $ 959,307 | Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets December 31, 2021 December 31, 2020 Prepaid consulting $ 930,893 $ 76,663 Insurance 987 665 Prepaid costs 27,427 - Total $ 959,307 $ 77,328 |
Fixed assets (Tables)
Fixed assets (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Property, Plant and Equipment [Abstract] | ||
Schedule of Fixed Assets | Fixed assets consist of the following: Schedule of Fixed Assets June 30, 2022 December 31, 2021 Land $ 235,223 $ 235,223 Vehicles 50,514 50,514 Computer hardware 5,935 5,935 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 301,159 301,159 Accumulated depreciation (19,461 ) (17,135 ) Property and equipment, net $ 281,698 $ 284,024 | Fixed assets consist of the following: Schedule of Fixed Assets December 31, 2021 December 31, 2020 Land $ 235,223 $ - Vehicles 50,514 - Computer hardware 5,935 10,747 Office furniture and equipment 7,912 3,639 Shipping and other equipment 1,575 7,023 Total 301,159 21,409 Accumulated depreciation (17,135 ) (16,350 ) Property and equipment, net $ 284,024 $ 5,059 |
Other assets (Tables)
Other assets (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | ||
Schedule of Other Assets | Other assets consist of the following: Schedule of Other Assets June 30, 2022 December 31, 2021 Prepaid consulting $ 33,340 $ 108,673 Deposit 39,823 39,823 Licenses, net 3,331,840 129,075 Total $ 3,405,003 $ 277,571 | Other assets consist of the following: Schedule of Other Assets December 31, 2021 December 31, 2020 Prepaid consulting $ 108,673 $ 39,914 Deposit 39,823 11,638 Licenses, net 129,075 140,370 Total $ 277,571 $ 191,922 |
Schedule of Net Licenses | Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses June 30, 2022 December 31, 2021 Licenses $ 3,461,122 $ 153,552 Accumulated amortization (129,282 ) (24,477 ) Licenses, net $ 3,331,840 $ 129,075 | Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses December 31, 2021 December 31, 2020 License $ 153,552 $ 153,552 Accumulated amortization (24,477 ) (13,182 ) Licenses, net $ 129,075 $ 140,370 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | ||
Schedule of Future Minimum Lease Payments | Future minimum lease payments as of December 31, 2022, are as follows: Schedule of Future Minimum Lease Payments For the year ending December 31, 2022 $ 13,062 2023 $ 8,612 | Schedule of Future Minimum Lease Payments 2022 26,460 2023 8,911 Total lease payment 35,371 Less: Imputed Interest (1,187 ) Present value of lease liabilities 34,184 Current portion (25,374 ) Non-current portion 8,810 |
Schedule of Notes Payable Related Parties | Notes payable-related parties consist of: Schedule of Notes Payable Related Parties December 31, 2021 December 31, 2020 $ 2,356 $ 7,054 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10 December 31, 2019 $ 2,356 $ 7,054 Three notes payable – Chief Executive Officer, unsecured, including interest at 8 10 10 December 31, 2019 27,577 26,064 One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues 534,544 534,646 Note payable – Chief Financial Officer, unsecured, including interest at 8 December 31, 2019 118,400 112,000 Three notes payable – Business Advisory Board Member, unsecured, including interest at 8 10 0.005 0.004 April 20, 2019 282,334 264,334 965,211 944,098 Less debt discount - - $ 965,211 $ 944,098 |
Income taxes (Tables)
Income taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Schedule of Income tax Expense | Schedule of Income tax Expense December 31, 2021 December 31, 2020 Expected income tax at statutory rate $ (621,735 ) $ (458,619 ) State tax 168 168 Meals & Entertainments 295 - Permanent differences 404,577 295,578 Other (71,992 ) (336 ) Change in valuation allowance 289,487 163,209 Provision for income taxes $ 800 $ - |
Schedule of Deferred Tax Assets and Liabilities | The significant components of deferred income tax assets and liabilities at December 31, 2021 and 2020 are as follows: Schedule of Deferred Tax Assets and Liabilities December 31, 2021 December 31, 2020 Net operating loss carry-forward $ 1,450,896 $ 1,668,324 Valuation allowance (1,450,896 ) (1,668,324 ) Net deferred tax asset $ - $ - |
Organization and Business Des_2
Organization and Business Description (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | 60 Months Ended | ||||
Aug. 04, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||||||||
Entity incorporation date | Aug. 06, 2007 | Aug. 06, 2007 | ||||||
Net loss | $ 1,190,757 | $ 637,242 | $ 1,791,680 | $ 824,165 | $ 2,961,445 | $ 2,199,901 | $ (14,200,000) | |
Unusual or infrequent item, description | the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91% | |||||||
Net loss | $ (1,190,757) | $ (637,242) | $ (1,791,680) | $ (824,165) | $ (2,961,445) | $ (2,199,901) | $ 14,200,000 |
Schedule of Change in Derivativ
Schedule of Change in Derivative Liability (Details) - USD ($) | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | |||
Beginning Balance | $ 531,525 | $ 437,549 | $ 521,700 |
Issuance of new derivative liabilities | 424,716 | 1,077,756 | 562,620 |
Conversions to paid-in capital | (348,389) | (489,279) | (440,270) |
Change in fair market value of derivative liabilities | (265,508) | (494,501) | (206,501) |
Ending Balance | $ 342,344 | $ 531,525 | $ 437,549 |
Basis of presentation and sig_4
Basis of presentation and significant accounting policies (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Property, Plant and Equipment [Line Items] | ||||||
Payments description | Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail | Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retai | ||||
Cash, FDIC insured amount | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 12,349 |
Derivative liabilities | 342,344 | $ 342,344 | $ 531,525 | $ 437,549 | ||
Antidilutive securities excluded from computation of earnings per share, amount | 167,223,808 | 286,251,995 | 95,273,690 | 579,347,525 | ||
Depreciation | $ 2,326 | $ 1,331 | $ 6,772 | $ 389 | ||
Amortization expense | 104,805 | 3,296 | 11,295 | 6,591 | ||
Research and development expense | 597,893 | $ 132,085 | 902,052 | $ 151,782 | 794,750 | 561,990 |
Right-of-use asset | 21,530 | 21,530 | 34,184 | 58,976 | ||
Lease liability | 21,530 | 21,530 | $ 34,184 | |||
Maximum [Member] | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Cash, FDIC insured amount | $ 250,000 | $ 250,000 | $ 250,000 |
Restricted cash (Details Narrat
Restricted cash (Details Narrative) - USD ($) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Cash and Cash Equivalents [Abstract] | ||
Restricted cash and non-cash equivalents | $ 10,000 | $ 10,000 |
Annual interest rate | 0.60% | 0.60% |
Restricted cash description | This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011 | This certificate matures on June 17, 2022, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011 |
Schedule of Prepaid Expenses an
Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Prepaid Expense And Other Current Assets | |||
Prepaid consulting | $ 461,820 | $ 930,893 | $ 76,663 |
Insurance | 1,094 | 987 | 665 |
Prepaid costs | 67,596 | 27,427 | |
Total | $ 530,510 | $ 959,307 | $ 77,328 |
Schedule of Fixed Assets (Detai
Schedule of Fixed Assets (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Property, Plant and Equipment [Line Items] | |||
Total | $ 301,159 | $ 301,159 | $ 21,409 |
Accumulated depreciation | (19,461) | (17,135) | (16,350) |
Property and equipment, net | 281,698 | 284,024 | 5,059 |
Land [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Total | 235,223 | 235,223 | |
Vehicles [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Total | 50,514 | 50,514 | |
Computer Equipment [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Total | 5,935 | 5,935 | 10,747 |
Office Furniture and Equipment [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Total | 7,912 | 7,912 | 3,639 |
Shipping and Other Equipment [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Total | $ 1,575 | $ 1,575 | $ 7,023 |
Fixed assets (Details Narrative
Fixed assets (Details Narrative) - USD ($) | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Property, Plant and Equipment [Abstract] | ||||
Depreciation expense | $ 2,326 | $ 1,331 | $ 6,772 | $ 389 |
Schedule of Other Assets (Detai
Schedule of Other Assets (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |||
Prepaid consulting | $ 33,340 | $ 108,673 | $ 39,914 |
Deposit | 39,823 | 39,823 | 11,638 |
Licenses, net | 3,331,840 | 129,075 | 140,370 |
Total | $ 3,405,003 | $ 277,571 | $ 191,922 |
Schedule of Net Licenses (Detai
Schedule of Net Licenses (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |||
License | $ 3,461,122 | $ 153,552 | $ 153,552 |
Accumulated amortization | (129,282) | (24,477) | (13,182) |
Licenses, net | $ 3,331,840 | $ 129,075 | $ 140,370 |
Other assets (Details Narrative
Other assets (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
Mar. 25, 2022 | Feb. 23, 2022 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Number of shares issuance value | $ 100,000 | $ 7,999 | $ 445,000 | $ 225,498 | $ 285,499 | |||
Payment to acquire license | 200,000 | |||||||
Amortization of intangible assets | $ 104,805 | $ 3,296 | $ 11,295 | $ 6,591 | ||||
Common Stock [Member] | ||||||||
Number of shares issuance | 160,000 | 44,500,000 | 3,571,679 | 4,850,075 | ||||
Number of shares issuance value | $ 160 | $ 44,500 | $ 3,571 | $ 4,850 | ||||
Exclusive patent license agreement [Member] | Convertible Promissory Note [Member] | ||||||||
Patent expires agreement date | Dec. 31, 2032 | |||||||
Amortized useful life | 10 years | |||||||
Exclusive patent license agreement [Member] | Convertible Promissory Note [Member] | Common Stock [Member] | ||||||||
Number of shares issuance | 149,402,390 | |||||||
Share price | $ 0.0208 | |||||||
Number of shares issuance value | $ 3,107,570 | |||||||
Assets Transfer and License Agreement [Member] | ||||||||
Amortized life of agreement | 5 years | |||||||
Assets Transfer and License Agreement [Member] | Initial Payment [Member] | ||||||||
Payment to acquire license | $ 200,000 | |||||||
Assets Transfer and License Agreement [Member] | Second Payment [Member] | ||||||||
Payment to acquire license | $ 1,800,000 |
Notes Payable-Related Party (De
Notes Payable-Related Party (Details Narrative) - USD ($) | 6 Months Ended | |||
Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | Dec. 31, 2020 | |
Debt Instrument [Line Items] | ||||
Notes payable related party | $ 975,739 | $ 965,211 | $ 944,098 | |
Officers and Directors [Member] | ||||
Debt Instrument [Line Items] | ||||
Notes payable related party | 975,739 | $ 965,211 | ||
Accrued interest | 12,956 | $ 12,956 | ||
Debt conversion amount | $ 251,000 | |||
Officers and Directors [Member] | Minimum [Member] | ||||
Debt Instrument [Line Items] | ||||
Debt conversion price | $ 0.004 | |||
Officers and Directors [Member] | Maximum [Member] | ||||
Debt Instrument [Line Items] | ||||
Debt conversion price | $ 0.005 |
Convertible Notes Payable (Deta
Convertible Notes Payable (Details Narrative) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
Jun. 30, 2022 USD ($) shares | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) shares | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) $ / shares shares | Dec. 31, 2020 USD ($) $ / shares shares | Dec. 30, 2021 | Dec. 30, 2020 $ / shares | |
Debt Instrument [Line Items] | ||||||||
Debt original issuance discount | $ 315,000 | $ 252,500 | $ 538,750 | $ 315,000 | ||||
Debt discount | ||||||||
Loss on derivative liability | $ 43,184 | $ 84,298 | 109,716 | 432,553 | 539,006 | 247,620 | ||
Additional paid in capital on convertible debt features | 489,279 | |||||||
Derivative liabilities | 342,344 | 342,344 | 531,525 | 437,549 | ||||
Interest expenses | 195,392 | $ 196,083 | 345,390 | 278,011 | 611,794 | 302,481 | ||
Seven Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative issuance liability | 562,620 | |||||||
Convertible Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Debt discount | 249,383 | $ 249,383 | 225,800 | |||||
Debt maturity date description | amortized through June 2023 | |||||||
Interest expenses | $ 313,917 | $ 248,238 | ||||||
Interest expenses | $ 541,612 | $ 251,801 | ||||||
Measurement Input, Expected Term [Member] | Convertible Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input term | 1 year | |||||||
Measurement Input, Expected Term [Member] | Convertible Notes Payable [Member] | Seven Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input term | 1 year | |||||||
Derivative [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative issuance liability | $ 1,077,756 | |||||||
Loss on derivative liability | $ 539,006 | |||||||
Derivative [Member] | Seven Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Loss on derivative liability | $ 247,620 | |||||||
Derivative [Member] | Measurement Input, Expected Dividend Rate [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0 | |||||||
Derivative [Member] | Measurement Input, Expected Dividend Rate [Member] | Seven Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0 | |||||||
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.05 | |||||||
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member] | Seven Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.17 | |||||||
Minimum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | $ / shares | 0.0039 | |||||||
Minimum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member] | Seven Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | $ / shares | 0.0008 | |||||||
Minimum [Member] | Derivative [Member] | Measurement Input, Share Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | $ / shares | 0.0217 | |||||||
Minimum [Member] | Derivative [Member] | Measurement Input, Share Price [Member] | Seven Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | $ / shares | 0.0023 | |||||||
Minimum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 197 | |||||||
Minimum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member] | Seven Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 237 | |||||||
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.29 | |||||||
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member] | Seven Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 1.48 | |||||||
Maximum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | $ / shares | 0.0351 | |||||||
Maximum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member] | Seven Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | $ / shares | 0.0042 | |||||||
Maximum [Member] | Derivative [Member] | Measurement Input, Share Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | $ / shares | 0.0540 | |||||||
Maximum [Member] | Derivative [Member] | Measurement Input, Share Price [Member] | Seven Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | $ / shares | 0.0056 | |||||||
Maximum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 264 | |||||||
Maximum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member] | Seven Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 260 | |||||||
Convertible Promissory Note [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Debt principal amount | 337,500 | 337,500 | $ 572,250 | $ 336,500 | ||||
Debt original issuance discount | 315,000 | 538,750 | 315,000 | |||||
Debt discount | $ 22,500 | $ 22,500 | $ 33,500 | $ 21,500 | ||||
Interest rate percentage | 12% | |||||||
Debt maturity date description | January 1, 2023 to June 27, 2023 | mature on dates ranging from January 25, 2022 to December 15, 2022 | mature on dates ranging from February 3, 2021 to December 17, 2021 | |||||
Debt conversion description | The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. | The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150% | The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to 61% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150% | |||||
Common shares reserve for future issuance | shares | 167,223,808 | 167,223,808 | ||||||
Derivative issuance liability | $ 424,716 | |||||||
Loss on derivative liability | $ 109,716 | |||||||
Common shares reserve | shares | 95,273,690 | 579,347,525 | ||||||
Convertible Promissory Note [Member] | Measurement Input, Expected Term [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input term | 1 year | |||||||
Convertible Promissory Note [Member] | Derivative [Member] | Measurement Input, Expected Dividend Rate [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0 | 0 | ||||||
Convertible Promissory Note [Member] | Minimum [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Interest rate percentage | 10% | 10% | 10% | |||||
Convertible Promissory Note [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.48 | 0.48 | ||||||
Convertible Promissory Note [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.0127 | 0.0127 | ||||||
Convertible Promissory Note [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Share Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.020 | 0.020 | ||||||
Convertible Promissory Note [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 158 | 158 | ||||||
Convertible Promissory Note [Member] | Maximum [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Interest rate percentage | 12% | 12% | 12% | |||||
Convertible Promissory Note [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 2.89 | 2.89 | ||||||
Convertible Promissory Note [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.0143 | 0.0143 | ||||||
Convertible Promissory Note [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Share Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.027 | 0.027 | ||||||
Convertible Promissory Note [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 216 | 216 | ||||||
Convertible Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Convertible notes payable | $ 322,124 | $ 322,124 | ||||||
Debt conversion of convertible shares | shares | 24,167,728 | |||||||
Additional paid in capital on convertible debt features | $ 348,389 | |||||||
Convertible Notes Payable [Member] | Derivative [Member] | Measurement Input, Expected Dividend Rate [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0 | 0 | 0 | 0 | ||||
Convertible Notes Payable [Member] | Derivative [Member] | Measurement Input, Expected Term [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input term | 5 months 26 days | |||||||
Convertible Notes Payable [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.06 | 0.12 | ||||||
Convertible Notes Payable [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.012 | 0.012 | 0.0136 | 0.00055 | ||||
Convertible Notes Payable [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Share Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.018 | 0.018 | 0.022 | 0.001 | ||||
Convertible Notes Payable [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 166 | 166 | 125 | 170 | ||||
Convertible Notes Payable [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.51 | 0.51 | ||||||
Convertible Notes Payable [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Expected Term [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input term | 5 months 23 days | 25 days | ||||||
Convertible Notes Payable [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.29 | 0.89 | ||||||
Convertible Notes Payable [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.016 | 0.016 | 0.035 | 0.0039 | ||||
Convertible Notes Payable [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Share Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.026 | 0.026 | 0.057 | 0.010 | ||||
Convertible Notes Payable [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 191 | 191 | 251 | 305 | ||||
Convertible Notes Payable [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 2.88 | 2.88 | ||||||
Convertible Notes Payable [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Expected Term [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input term | 6 months | 6 months | ||||||
Remaining Convertible Notes [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liabilities | $ 342,344 | $ 342,344 | $ 531,525 | $ 437,539 | ||||
Gain on derivative liabilities | $ 265,508 | |||||||
Remaining Convertible Notes [Member] | Convertible Notes Payable [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Gain on derivative liabilities | $ 494,501 | $ 206,501 | ||||||
Remaining Convertible Notes [Member] | Measurement Input, Share Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.021 | 0.021 | 0.029 | 0.0064 | ||||
Remaining Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0 | 0 | 0 | 0 | ||||
Remaining Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 2.80 | 2.80 | 0.39 | 0.12 | ||||
Remaining Convertible Notes [Member] | Measurement Input, Exercise Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 0.0129 | 0.0129 | 0.0029 | |||||
Remaining Convertible Notes [Member] | Minimum [Member] | Measurement Input, Conversion Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | $ / shares | 0.0123 | |||||||
Remaining Convertible Notes [Member] | Minimum [Member] | Measurement Input, Price Volatility [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 127 | 127 | 165 | 2.41 | ||||
Remaining Convertible Notes [Member] | Minimum [Member] | Measurement Input, Expected Term [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input term | 6 months 14 days | 6 months 10 days | 9 months 3 days | |||||
Remaining Convertible Notes [Member] | Maximum [Member] | Measurement Input, Conversion Price [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | $ / shares | 0.0127 | |||||||
Remaining Convertible Notes [Member] | Maximum [Member] | Measurement Input, Price Volatility [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input | 165 | 165 | 218 | 2.54 | ||||
Remaining Convertible Notes [Member] | Maximum [Member] | Measurement Input, Expected Term [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Derivative liability, measurement input term | 11 months 26 days | 11 months 15 days | 11 months 15 days | |||||
Convertible Note [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Debt conversion of convertible shares | shares | 21,690,671 | 174,556,025 | ||||||
Additional paid in capital on convertible debt features | $ 440,270 | |||||||
Debt conversion of convertible shares, value | $ 529,735 | $ 262,882 |
Equity (Details Narrative)
Equity (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
Jun. 15, 2020 | Jun. 09, 2020 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Aggregate authorized capital | 3,505,000,000 | 3,505,000,000 | 3,505,000,000 | |||||
Common stock, shares authorized | 3,500,000,000 | 3,500,000,000 | 3,500,000,000 | 3,500,000,000 | ||||
Common stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | ||||
Preferred stock, shares authorized | 5,000,000 | 5,000,000 | 5,000,000 | 5,000,000 | ||||
Common stock, shares issued | 2,552,228,460 | 2,552,228,460 | 2,311,123,860 | 2,233,741,391 | ||||
Common stock, shares outstanding | 2,552,228,460 | 2,552,228,460 | 2,311,123,860 | 2,233,741,391 | ||||
Common stock issued for cash | $ 100,000 | $ 7,999 | $ 445,000 | $ 225,498 | $ 285,499 | |||
Common stock issued for conversion of notes | 206,849 | $ 246,450 | $ 322,124 | $ 246,450 | $ 529,735 | $ 262,882 | ||
Preferred stock, shares issued | 0 | |||||||
Preferred stock, shares outstanding | 0 | |||||||
Convertible Notes Payable [Member] | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Common stock issued for cash, shares | 18,181,818 | |||||||
Common stock issued for cash | $ 60,000 | |||||||
Common Stock [Member] | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Common stock issued for cash, shares | 160,000 | 44,500,000 | 3,571,679 | 4,850,075 | ||||
Common stock issued for cash | $ 160 | $ 44,500 | $ 3,571 | $ 4,850 | ||||
Common stock issued for conversion of notes, shares | 15,230,280 | 7,663,763 | 24,167,728 | 7,663,763 | 21,690,671 | 174,556,025 | ||
Common stock issued for conversion of notes | $ 15,230 | $ 7,664 | $ 24,167 | $ 7,664 | $ 21,691 | $ 174,556 | ||
Common Stock [Member] | Convertible Notes Payable [Member] | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Common stock issued for cash, shares | 21,690,671 | 174,556,025 | ||||||
Common stock issued for cash | $ 1,019,014 | $ 703,152 | ||||||
Common stock issued for conversion of notes, shares | 24,167,728 | 21,690,671 | ||||||
Common stock issued for conversion of notes | $ 322,124 | $ 1,019,014 | ||||||
Common Stock [Member] | Land Development [Member] | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Common stock issued for cash, shares | 1,500,000 | |||||||
Common stock issued for cash | $ 58,900 | |||||||
Common Stock [Member] | Salaries [Member] | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Common stock issued for cash, shares | 1,034,482 | 8,341,723 | 78,681,818 | |||||
Common stock issued for cash | $ 29,999 | $ 239,799 | $ 495,900 | |||||
Common Stock [Member] | License [Member] | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Common stock issued for cash, shares | 149,402,390 | |||||||
Common stock issued for cash | $ 3,107,570 | |||||||
Common Stock [Member] | Prepaid fees [Member] | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Common stock issued for cash, shares | 6,000,000 | |||||||
Common stock issued for cash | $ 148,820 | |||||||
Common Stock [Member] | Consulting Services [Member] | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Common stock issued for cash, shares | 20,000,000 | 16,000,000 | 21,000,000 | 173,500,000 | ||||
Common stock issued for cash | $ 106,000 | $ 407,200 | $ 858,900 | $ 669,750 | ||||
Common Stock [Member] | Private Placement [Member] | ||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
Common stock issued for cash, shares | 44,500,000 | 4,850,075 | 192,375,737 | |||||
Common stock issued for cash | $ 445,000 | $ 285,500 | $ 607,500 |
Subsequent events (Details Narr
Subsequent events (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||
Aug. 09, 2022 | Aug. 04, 2022 | Jul. 25, 2022 | Jul. 15, 2022 | Jul. 13, 2022 | Feb. 24, 2022 | Feb. 14, 2022 | Jan. 14, 2022 | Jan. 04, 2022 | Jun. 15, 2020 | Feb. 28, 2022 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Subsequent Event [Line Items] | |||||||||||||||||
Conversion of common stock | $ 206,849 | $ 246,450 | $ 322,124 | $ 246,450 | $ 529,735 | $ 262,882 | |||||||||||
Common stock issued for cash | $ 100,000 | $ 7,999 | $ 445,000 | $ 225,498 | $ 285,499 | ||||||||||||
Common Stock [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Conversion of common stock, shares | 15,230,280 | 7,663,763 | 24,167,728 | 7,663,763 | 21,690,671 | 174,556,025 | |||||||||||
Conversion of common stock | $ 15,230 | $ 7,664 | $ 24,167 | $ 7,664 | $ 21,691 | $ 174,556 | |||||||||||
Shares issued for consulting service | 16,000,000 | 3,500,000 | 16,000,000 | 3,500,000 | 21,000,000 | 173,500,000 | |||||||||||
Conversion of common stock, shares | 160,000 | 44,500,000 | 3,571,679 | 4,850,075 | |||||||||||||
Common stock issued for cash | $ 160 | $ 44,500 | $ 3,571 | $ 4,850 | |||||||||||||
Common Stock [Member] | Private Placement [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Conversion of common stock, shares | 44,500,000 | 4,850,075 | 192,375,737 | ||||||||||||||
Common stock issued for cash | $ 445,000 | $ 285,500 | $ 607,500 | ||||||||||||||
Common Stock [Member] | Consulting Services [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Conversion of common stock, shares | 20,000,000 | 16,000,000 | 21,000,000 | 173,500,000 | |||||||||||||
Common stock issued for cash | $ 106,000 | $ 407,200 | $ 858,900 | $ 669,750 | |||||||||||||
Subsequent Event [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Conversion of common stock | $ 15,000,000 | ||||||||||||||||
Subsequent Event [Member] | Private Placement [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Conversion of common stock, shares | 149,402,390 | ||||||||||||||||
Subsequent Event [Member] | Accrued Salaries [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Conversion of common stock, shares | 1,034,482 | ||||||||||||||||
Common stock issued for cash | $ 30,000 | ||||||||||||||||
Subsequent Event [Member] | Common Stock [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Conversion of common stock, shares | 4,095,000 | 1,701,389 | 2,777,778 | 4,158,759 | 4,778,689 | ||||||||||||
Conversion of common stock | $ 51,188 | $ 21,438 | $ 35,000 | $ 56,975 | $ 58,300 | ||||||||||||
Subsequent Event [Member] | Common Stock [Member] | Private Placement [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Shares issued price per share | $ 0.01 | $ 0.01 | |||||||||||||||
Conversion of common stock, shares | 10,000,000 | 24,500,000 | |||||||||||||||
Subsequent Event [Member] | Common Stock [Member] | Consulting Services [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Shares issued for consulting service | 5,000,000 | ||||||||||||||||
Shares issued price per share | $ 0.02 | ||||||||||||||||
Subsequent Event [Member] | Preferred Stock [Member] | |||||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||||
Shares issued price per share | $ 0.001 | ||||||||||||||||
Conversion of common stock, shares | 2 |
Schedule of Future Minimum Leas
Schedule of Future Minimum Lease Payments (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Commitments and Contingencies Disclosure [Abstract] | |||
2022 | $ 13,062 | ||
2022 | 8,612 | $ 26,460 | |
2023 | 8,911 | ||
Total lease payment | 35,371 | ||
Less: Imputed Interest | (1,187) | ||
Present value of lease liabilities | 21,530 | 34,184 | |
Current portion | (19,377) | (25,374) | $ (24,792) |
Non-current portion | $ 2,153 | $ 8,810 | $ 34,184 |
Schedule of Notes Payable Relat
Schedule of Notes Payable Related Parties (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Short-Term Debt [Line Items] | |||
Notes payable related party, current | $ 975,739 | $ 965,211 | $ 944,098 |
Less debt discount | |||
Notes payable related party, non-current | 965,211 | 944,098 | |
Notes Payable One [Member] | |||
Short-Term Debt [Line Items] | |||
Notes payable related party, current | 2,356 | 7,054 | |
Notes Payable Two [Member] | |||
Short-Term Debt [Line Items] | |||
Notes payable related party, current | 27,577 | 26,064 | |
Notes Payable Three [Member] | |||
Short-Term Debt [Line Items] | |||
Notes payable related party, current | 534,544 | 534,646 | |
Notes Payable Four [Member] | |||
Short-Term Debt [Line Items] | |||
Notes payable related party, current | 118,400 | 112,000 | |
Notes Payable Five [Member] | |||
Short-Term Debt [Line Items] | |||
Notes payable related party, current | $ 282,334 | $ 264,334 |
Schedule of Notes Payable Rel_2
Schedule of Notes Payable Related Parties (Details) (Parenthetical) | 12 Months Ended |
Dec. 31, 2021 $ / shares | |
Scientific Advisory Board [Member] | |
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |
Debt interest percentage | 10% |
Debt maturity date | Dec. 31, 2019 |
Scientific Advisory Board [Member] | Notes Payable One [Member] | |
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |
Debt interest percentage | 10% |
Scientific Advisory Board [Member] | Notes Payable Three [Member] | |
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |
Debt interest percentage | 10% |
Chief Executive Officer [Member] | Notes Payable One [Member] | |
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |
Debt interest percentage | 8% |
Chief Financial Officer [Member] | |
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |
Debt interest percentage | 8% |
Debt maturity date | Dec. 31, 2019 |
Business Advisory Board [Member] | |
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |
Debt maturity date | Apr. 20, 2019 |
Business Advisory Board [Member] | Notes Payable One [Member] | |
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |
Debt interest percentage | 8% |
Share price | $ 0.005 |
Business Advisory Board [Member] | Notes Payable Two [Member] | |
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | |
Debt interest percentage | 10% |
Share price | $ 0.004 |
Commitments and Contingencies_2
Commitments and Contingencies (Details Narrative) | 6 Months Ended | 12 Months Ended | |||
Mar. 25, 2022 USD ($) | Jun. 30, 2022 USD ($) ft² | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) ft² | Dec. 31, 2020 USD ($) | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||
Area of land | ft² | 1,700 | ||||
Lease contract term | 36 months | ||||
Lease expiration date | Apr. 30, 2023 | ||||
Payment for rent | $ 22,768 | $ 25,993 | |||
Operating lease discount rate | 5% | ||||
Payment to acquire license | $ 200,000 | ||||
Assets Transfer and License Agreement [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||
Amortized life of agreement | 5 years | ||||
Assets Transfer and License Agreement [Member] | Initial Payment [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||
Payment to acquire license | $ 200,000 | ||||
Assets Transfer and License Agreement [Member] | Second Payment [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||
Payment to acquire license | $ 1,800,000 | ||||
Effective March 1, 2020 [Member] | Lease Agreement [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||
Area of land | ft² | 1,700 | ||||
Lease contract term | 36 months | ||||
Lease expiration date | Apr. 30, 2023 | ||||
Payment for rent | $ 12,522 | ||||
Lease description | The lease will expire in 2023. The weighted average discount rate used for this lease is 5% (average borrowing rate of the Company) | ||||
Operating lease discount rate | 5% |
Related party transactions (Det
Related party transactions (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||
Jun. 18, 2021 | Jun. 17, 2020 | Jun. 15, 2020 | Jun. 09, 2020 | Nov. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Accrued interest revenue percentage | 0.50% | ||||||||||||
Common stock issued for cash | $ 100,000 | $ 7,999 | $ 445,000 | $ 225,498 | $ 285,499 | ||||||||
Common Stock [Member] | |||||||||||||
Common stock issued for cash, shares | 160,000 | 44,500,000 | 3,571,679 | 4,850,075 | |||||||||
Common stock issued for cash | $ 160 | $ 44,500 | $ 3,571 | $ 4,850 | |||||||||
Common Stock [Member] | Consulting Services [Member] | |||||||||||||
Common stock issued for cash, shares | 20,000,000 | 16,000,000 | 21,000,000 | 173,500,000 | |||||||||
Common stock issued for cash | $ 106,000 | $ 407,200 | $ 858,900 | $ 669,750 | |||||||||
Convertible Notes Payable [Member] | |||||||||||||
Common stock issued for cash, shares | 18,181,818 | ||||||||||||
Common stock issued for cash | $ 60,000 | ||||||||||||
Convertible Notes Payable [Member] | Common Stock [Member] | |||||||||||||
Common stock issued for cash, shares | 21,690,671 | 174,556,025 | |||||||||||
Common stock issued for cash | $ 1,019,014 | $ 703,152 | |||||||||||
Officer [Member] | |||||||||||||
Accrued officers salary | $ 439,534 | $ 663,100 | |||||||||||
Timothy G Dixon [Member] | |||||||||||||
Convertible notes payable | $ 60,000 | ||||||||||||
Convertible notes payable interest rate | 5% | ||||||||||||
Three Officers And One Director [Member] | Restricted Stock [Member] | Common Stock [Member] | |||||||||||||
Common stock issued for cash, shares | 122,000,000 | ||||||||||||
Common stock issued for cash | $ 437,400 | ||||||||||||
One Officers And One Director [Member] | Restricted Stock [Member] | Common Stock [Member] | |||||||||||||
Common stock issued for cash, shares | 22,500,000 | 29,000,000 | |||||||||||
Common stock issued for cash | $ 154,500 | $ 240,000 | |||||||||||
One Officers [Member] | Restricted Stock [Member] | Common Stock [Member] | Accrued Salaries [Member] | |||||||||||||
Common stock issued for cash, shares | 7,544,848 | ||||||||||||
Common stock issued for cash | $ 239,800 | ||||||||||||
One Officer One Director [Member] | Restricted Stock [Member] | Common Stock [Member] | |||||||||||||
Common stock issued for cash, shares | 2,000,000 | ||||||||||||
Common stock issued for cash | $ 94,600 | ||||||||||||
Four Officer One Director [Member] | Restricted Stock [Member] | Common Stock [Member] | |||||||||||||
Common stock issued for cash, shares | 7,000,000 | ||||||||||||
Common stock issued for cash | $ 224,000 |
Schedule of Income tax Expense
Schedule of Income tax Expense (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | ||
Expected income tax at statutory rate | $ (621,735) | $ (458,619) |
State tax | 168 | 168 |
Meals & Entertainments | 295 | |
Permanent differences | 404,577 | 295,578 |
Other | (71,992) | (336) |
Change in valuation allowance | 289,487 | 163,209 |
Provision for income taxes | $ 800 |
Schedule of Deferred Tax Assets
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Income Tax Disclosure [Abstract] | ||
Net operating loss carry-forward | $ 1,450,896 | $ 1,668,324 |
Valuation allowance | (1,450,896) | (1,668,324) |
Net deferred tax asset |
Income taxes (Details Narrative
Income taxes (Details Narrative) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | ||
Federal and state income taxes rate | 30% | |
Federal net operating loss carryfowards | $ 7.5 | $ 6.5 |
State net operating loss carryfowards | 5.5 | $ 4.5 |
Net operating loss carryforwards are available to offset taxable income | $ 5 | |
Net operating loss carryforwards, expiration, description | expires beginning in fiscal 2032 |